Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metaboli...(ommercializing drugs that are safe andef...)
Navigation Links
| HOME >> BIOLOGY >> TECHNOLOGY |
Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases
Date:9/13/2007
ommercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such products. Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2006, and its quarterly report on Form 10-Q for the quarter ended June 30, 2007, which are on file with the SEC. Copies of these and other documents are available from the Company.
In this press release, unless the context requires otherwise, "Isis," "Company," "we," "our," and "us" refers to Isis Pharmaceuticals and its subsidiaries.
Isis Pharmaceuticals, Ibis Biosciences and Ibis T5000 are registered trademarks or trademarks of Isis Pharmaceuticals, Inc.
'/>"/>
| SOURCE Isis Pharmaceuticals, Inc. Copyright©2007 PR Newswire. All rights reserved |
Related biology technology :
1. WARF enters licensing agreements for stem cell products
2. Virent enters agreement with Shell Oil unit to make hydrogen with biomass
3. Software company enters health space with RFID solutions on hold
4. Lucigen Corp. enters global licensing agreement
5. Call centers and customer service: The good, the bad, and the clueless
6. GE Healthcare enters agreement with Canadian health authority
7. Data centers: Buyers beware of over-hyped facilities
8. Data centers: Blowing smoke and raising red flags
9. Prodesse enters patent agreement with Roche
10. UW-Madison enters Kauffman grant competition
11. Applied Technology Centers to aid printing and manufacturing
Post Your Comments:
Breaking Biology Technology:Enerkem Awarded $50 Million Funding by U.S. Department of Energy for its Mississippi Biorefinery Project 2Enerkem Awarded $50 Million Funding by U.S. Department of Energy for its Mississippi Biorefinery Project 3Stephen Kasay Joins PharmaNet Development Group as Chief Information Officer 2AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia 2AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia 3WuXi PharmaTech Selects Labcyte POD(TM) 810 Platform for High-Throughput Screening 2
[0] Enerkem Awarded $50 Million Funding by U.S. Department of Energy for its Mississippi Biorefinery Project[0] Stephen Kasay Joins PharmaNet Development Group as Chief Information Officer[0] AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia[0] WuXi PharmaTech Selects Labcyte POD(TM) 810 Platform for High-Throughput Screening
Other Biology Technology:ARRIVE Registry Analysis Demonstrates Continued Safety and Efficacy of TAXUS(R) Stent in Complex Real-World Patients 2ARRIVE Registry Analysis Demonstrates Continued Safety and Efficacy of TAXUS(R) Stent in Complex Real-World Patients 3ARRIVE Registry Analysis Demonstrates Continued Safety and Efficacy of TAXUS(R) Stent in Complex Real-World Patients 4Blood Donations in U.S. Testing Positive for Chagas' Disease 2Blood Donations in U.S. Testing Positive for Chagas' Disease 3Blood Donations in U.S. Testing Positive for Chagas' Disease 4Response Genetics' CEO to Discuss Advances in Optimizing Therapy through Pharmacogenomics as Part of a Series of Presentations at AACR-NCI-EORTC International Conference 2Response Genetics' CEO to Discuss Advances in Optimizing Therapy through Pharmacogenomics as Part of a Series of Presentations at AACR-NCI-EORTC International Conference 3
ARRIVE Registry Analysis Demonstrates Continued Safety and Efficacy of TAXUS(R) Stent in Complex Real-World PatientsBlood Donations in U.S. Testing Positive for Chagas' DiseaseResponse Genetics' CEO to Discuss Advances in Optimizing Therapy through Pharmacogenomics as Part of a Series of Presentations at AACR-NCI-EORTC International Conference
Breaking Biology News(10 mins):Study shows nearly 1/3 of human genome is involved in gingivitis 2Study shows nearly 1/3 of human genome is involved in gingivitis 3White, but not pure 2White, but not pure 3Eli Lilly 26 Company and ScinoPharm Taiwan Ltd Announce Settlement of Gemcitabine Litigation 13272 1Eli Lilly 26 Company and ScinoPharm Taiwan Ltd Announce Settlement of Gemcitabine Litigation 13272 2Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 1Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 2Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 3Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 4Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 5Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 6Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 7Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 8Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 9Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 10Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 11Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 12Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 13Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 14Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 15Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 16Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 17Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 18Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 19Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 20Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 21Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 22Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 23Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 24Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 25Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 26Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 27Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 28Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 29Aztech Controls Introduces Standardized Gas Sticks for Semiconductor Tool Hook Up 13268 1Aztech Controls Introduces Standardized Gas Sticks for Semiconductor Tool Hook Up 13268 2Aztech Controls Introduces Standardized Gas Sticks for Semiconductor Tool Hook Up 13268 3
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |